Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Dolby Laboratories, Inc. (DLB) vs Zoetis Inc (ZTS) Price & Performance

Dolby Laboratories, Inc.Trade
Zoetis IncTrade

Price performance (Past 24H)

Key statistics

Dolby Laboratories, Inc. vs Zoetis Inc — how do they compare? Dolby Laboratories, Inc. trades at $60.52 (market cap $5.75B), while Zoetis Inc trades at $72.55 (market cap $31.14B). The key difference: Zoetis Inc is far larger — about 5.4× Dolby Laboratories, Inc.'s market cap, and Zoetis Inc pays the higher dividend (2.81%). Which is the better fit depends on your goals.

DLBZTS
Market Cap
$5.75B$31.14B
Sector
IndustrialsHealth
52-Week High
$75.62$156.76
52-Week Low
$48.51$71.91
Enterprise Value
$5.12B$38.70B
Dividend Yield
2.35%2.81%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Dolby Laboratories, Inc.

DLB trades at $60.90, down 1.93% on the day, with a bullish technical signal from moving averages but bearish oscillators. The company has consistently beaten EPS estimates in recent quarters, including Q2 2026 with $0.69 actual versus $0.67 expected. Revenue has been stable around $1.3B annually, with a strong gross profit margin of 87.61% in 2025. Analyst consensus is a Buy with a price target of $87.50, suggesting significant upside. Recent news highlights growth in Dolby Atmos and automotive licensing.

The outlook for DLB is positive, supported by strong fundamentals and analyst optimism, but near-term execution risks and licensing volatility pose challenges. The stock's current valuation metrics, including a P/E of 26.11, appear reasonable given growth prospects. Key risks include revenue fluctuations and competitive pressures in the audio-video sector.

Zoetis Inc

Zoetis (ZTS) trades at $74.86, up 3.03% today but facing bearish technical signals with 16 sell indicators. The company reported mixed Q2 2026 results, beating EPS estimates but missing revenue expectations, while cutting full-year guidance due to softer pet healthcare demand. Strong fundamentals include a 27.69% net margin and 64.91% ROE, though valuation metrics show a P/E of 12.29 and P/S of 3.41.

The stock presents a value opportunity with analyst consensus target of $94.90 (27% upside), but faces near-term headwinds from competitive pressures and class action lawsuits. Investors should weigh strong profitability against slowing growth in companion animal segments and technical bearishness.

Returns comparison

Trailing returns across standard periods

About Dolby Laboratories, Inc.

Dolby Laboratories Inc develops audio and surround sound for cinema, broadcast, home audio systems, in-car entertainment systems, DVD players, games, televisions, and personal computers. The company generates three fourths of its revenue from licensing its technology to consumer electronics manufacturers around the world. The rest of revenue comes from equipment sales to professional producers and audio engineering services.

Read more on DLB

About Zoetis Inc

Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.

Read more on ZTS